Woody Joseph Fralin purchased $41K of RCEL

Woody Joseph Fralin purchased 10,000 shares of AVITA Medical, Inc. (RCEL) at an average of $4.09 ($4.09–$4.10) across 2 trades on 2026-06-03.

Original reporting
SEC EDGAR · Woody Joseph Fralin
Published Jun 5, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:58 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RCEL
Neutral
medium confidence
Mentioned
$RCEL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCELNeutralLow
01

Why it matters

The director's purchase modestly raises confidence but unlikely to move the stock significantly.

02

Market read

Small insider buy; limited immediate trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 4/10Novelty 4/10Timing: filing today

Background

Form 4 filing reports insider transactions; provides primary source data.

Company-level read

Ticker impact

$RCELNeutralMedium confidence
Context

Director Woody Joseph Fralin bought 10,000 shares of Avita Medical (RCEL) for $40,949, increasing his stake to 92,761 shares.

Expected impact

likely slight upward pressure as market digests insider buying.

Evidence & confidence

Purchase amount under $50k and director role suggest limited market impact; price may edge higher on positive sentiment.

Market effects

Minimal effect on medical device sector; insider activity is routine.

No regional impact.

Not globally relevant.

Counterpoint

Insider purchase could be a routine portfolio adjustment, not a bullish signal.

Key entities

  • Avita Medical, Inc.

    Medical device company listed on NASDAQ under RCEL.

  • Woody Joseph Fralin

    Director of Avita Medical.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RCELMed

Avita Medical Q3 Earnings Call Highlights

Avita Medical (RCEL) reported Q3 revenue of $600,000 for PermeaDerm, stable from Q2. Gross margin rose to 84%, and net loss narrowed to $6.2M. The company secured $10M in credit and alleviated going-concern doubts. RECELL revenue and manufacturing efficiencies drove improvements.

$RCELMed

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

$RCELMedAI 8/10

Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%

Avita Medical (NASDAQ:RCEL) reported Q2 net loss of $7.7M, nearly $3M better than Q1, with cash use down to $3.2M and cash of $11.1M at quarter end. The company raised its 2026 revenue outlook and said it is within Perceptive Advisors debt revenue covenants, including a $73M 2026 target. Q2 sales rose 18%.